A therapeutic being tested for nonalcoholic steatohepatitis (NASH) and liver fibrosis showed statistically significant improvement versus placebo on two primary endpoints in a one-year, Phase 2b trial ...
The unmet need in non-alcoholic steatohepatitis (NASH) is getting bigger and bigger. In the decade up to 2032, the number of diagnosed cases in seven major markets is forecast to grow by 4.5 million, ...
Nonalcoholic fatty liver disease (NAFLD) is very common; as many as 25 percent of adults around the world are impacted by the disorder. In NAFLD, liver cells die, damaging the organ. NALFD can also ...
WASHINGTON — In patients with cirrhosis associated with non-alcoholic steatohepatitis (NASH), 1 year of treatment with the investigational oral thyromimetic agent resmetirom (MGL-3196) was safe and ...
Madrigal Pharmaceuticals released positive results from its Phase 3 trial of resmetirom, its nonalcoholic steatohepatitis (NASH) and liver fibrosis drug. In the study, which included more than 950 ...
EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug ...
CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis ...
Fatty liver disease has become one of the most common liver problems across the world. Two forms stand out: non-alcoholic ...
Liver disease researchers, stumped by a complex disease, are looking for new investigative tools. Artificial intelligence might be one of them. At a small conference of the American Association for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback